Status:
COMPLETED
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa
Lead Sponsor:
The Hospital for Sick Children
Conditions:
Epidermolysis Bullosa
Eligibility:
All Genders
1-20 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy of trimethoprim in promoting wound healing and decreasing blister formation in patients with Epidermolysis Bullosa.
Detailed Description
Epidermolysis Bullosa (EB) comprises a series of hereditary disorders characterized by fragility of the skin and mucous membranes and the tendency of the skin to blister in response to minor friction ...
Eligibility Criteria
Inclusion
- Patients younger than 20 years of age
- Diagnosis of Recessive Dystrophic Epidermis Bullosa (RDEB)or Junctional Epidermis Bullosa (JEB)
- Signed consent/assent form
Exclusion
- Previous known allergy or intolerance to trimethoprim
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00380640
Start Date
September 1 2006
End Date
September 1 2007
Last Update
April 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8